Single-cell transcriptomic sequencing analysis of mechanistic insights into the IFN-γ signaling pathway in different tumor cells
Clinical and Translational Oncology · 01.08.2024 · 27 (2) · 745-755
DOI: 10.1007/s12094-024-03574-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, online erschienen am 01.08.2024. Verfasst von Lifang Zhou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Yixing People's Hospital, Affiliated to Jiangsu University, Yixing, 214200, China. Hauptthemen laut MEDLINE: Interferon-gamma, Tumor Microenvironment, Neoplasms, Single-Cell Analysis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: the Jiangsu Provincial Medical Association Laboratory Medicine Research Special Fund Project.
Abstract (Originalsprache)
PURPOSE: This study aimed to investigate the relationship between the interferon-gamma (IFN-γ) pathway in different tumor microenvironments (TME) and patients' prognosis, as well as the regulatory mechanisms of this pathway in tumor cells. METHODS: Using RNA-seq data from the TCGA database, we analyzed the predictive value of the IFN-γ pathway across various tumors. We employed a univariate Cox regression model to assess the prognostic significance of IFN-γ signaling in different tumor types. Additionally, we analyzed single-cell RNA sequencing (scRNA-seq) data from the Gene Expression Omnibus (GEO) database to examine the distribution characteristics of the IFN-γ pathway and explore its regulatory mechanisms, highlighting how IFN-γ influenced cellular interactions within the TME. RESULTS: Our analysis revealed a significant association between the IFN-γ pathway and adverse prognosis in pan-cancer tissues (P < 0.001). Interestingly, this correlation varied regarding positive and negative regulation across different tumor types. Through a detailed examination of scRNA-seq data, we found that the IFN-γ pathway exerted substantial regulatory effects on stromal and immune cells. In contrast, its expression and regulatory patterns in tumor cells exhibited diversity and heterogeneity. Further analysis indicated that the IFN-γ pathway not only enhanced the immunogenicity of tumor cells but also inhibited their proliferation. Cell-cell interaction analysis confirmed the pivotal role of the IFN-γ pathway within the overall regulatory network. Moreover, we identified HMGB2 (high mobility group box 2) in T cells as a potential key regulator of tumor cell proliferation. CONCLUSIONS: The IFN-γ pathway exhibited a dual function by both suppressing tumor cell proliferation and enhancing their immunogenicity, positioning it as a pivotal target for refined cancer diagnosis and cancer strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Yixing People's Hospital, Affiliated to Jiangsu University, Yixing, 214200, China.
- Department of Clinical Laboratory, Yixing People's Hospital, Affiliated to Jiangsu University, Yixing, 214200, China. staff1000@yxph.com.
Förderung
- the Jiangsu Provincial Medical Association Laboratory Medicine Research Special Fund Project
Zitieren
APA
Zhou, L., Lu, X., & Qiao, G. (2024). Single-cell transcriptomic sequencing analysis of mechanistic insights into the IFN-γ signaling pathway in different tumor cells. Clinical and Translational Oncology, 27(2), 745-755. https://doi.org/10.1007/s12094-024-03574-6
Vancouver
Zhou L, Lu X, Qiao G. Single-cell transcriptomic sequencing analysis of mechanistic insights into the IFN-γ signaling pathway in different tumor cells. Clinical and Translational Oncology. 2024;27(2):745-755. doi:10.1007/s12094-024-03574-6
BibTeX
@article{Zhou2024,
author = {Zhou, Lifang and Lu, Xu and Qiao, Guohong},
title = {Single-cell transcriptomic sequencing analysis of mechanistic insights into the IFN-γ signaling pathway in different tumor cells},
journal = {Clinical and Translational Oncology},
year = {2024},
volume = {27},
number = {2},
pages = {745--755},
doi = {10.1007/s12094-024-03574-6}
}
EUVIMED